Prof. Geiger’s team uses proteomics to study cancer and specifically investigates the mechanisms of cancer development, cell proliferation, and their response to therapy.
Prof. Geiger developed a technology called Super-Silac, which allows precise quantification of proteins from tumor tissues.
The main goal is to identify molecular markers that will enable physicians to predict the degree of aggressiveness of the tumor, in order to contribute to the development of anti-cancer drugs.
Prof. Geiger has collaborations with international and local academic and clinical institutions such as the Max Planck Institute of Biochemistry, and the University of Leiden in Germany, the Karolinska Institute, Sweden and the University of Barcelona, Barcelona.
Local collaborators include Weizmann institute of Science, Hebrew University of Jerusalem as well as Sheba, and Hadassah Medical centers.
Prof. Tamar Geiger PhD
Sackler Faculty of Medicine